Published in Cancer Detection and Prevention 2004; 28(2):127-142.

Celecoxib: a potent cyclooxygenase-2 inhibitor in cancer prevention

Kemal Kismet, MDa, M. Turan Akay, PhDb, Osman Abbasoglu, MDc, Aygün Ercan, MDd

a4th General Surgery Department, Ankara Research and Training Hospital, Ulucanlar, Ankara, Turkey bDepartment of Biology, Faculty of Science, Hacettepe University, 06532 Beytepe, Ankara, Turkey cDepartment of Surgery, School of Medicine, Hacettepe University, Sýhhiye, Ankara, Turkey dBeytepe Medical Center, Hacettepe University, Beytepe, Ankara, Turkey

Non-steroidal anti-inflammatory drugs (NSAIDs) are the most widely used therapeutic agents in the treatment of pain, inflammation and fever. They may also have a role in the management of cancer prevention, Alzheimer's disease and prophylaxis against cardiovascular disease. These drugs act primarily by inhibiting cyclooxygenase enzyme, which has two isoforms, cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2). Selective COX-2 inhibitors provide potent anti-inflammatory and analgesic effects without the side effects of gastric and renal toxicity and inhibition of platelet function. Celecoxib is a potent COX-2 inhibitor being developed for the treatment of rheumatoid arthritis and osteoarthritis. Chemoprevention is the use of pharmacological or natural agents to prevent, suppress, interrupt or reverse the process of carcinogenesis. For this purpose, celecoxib is being used for different cancer types. The effects of NSAIDs on tumor growth remain unclear, but are most likely to be multifocal. In this article, we reviewed COX-2 selectivity, the pharmacological properties of celecoxib, the use of celecoxib for cancer prevention and the mechanisms of chemoprevention.

KEY WORDS: Celecoxib, Non-steroidal anti-inflammatory drugs, Cyclooxygenase, Chemoprevention.